BRAVISSIMO study: 12-month results from the TASC A/B subgroup

Area of Science:

• Vascular Surgery
• Interventional Cardiology
• Endovascular Therapy

Background:

• Aortoiliac lesions impact peripheral artery disease management.
• Transatlantic Inter-Society Consensus (TASC) classification stratifies lesion complexity.
• Endovascular treatment is a key therapeutic option for these lesions.

Purpose of the Study:

• To evaluate the efficacy of endovascular therapy for TASC A and B aortoiliac lesions.
• To report the 12-month primary patency rates in the BRAVISSIMO trial cohort.
• To assess the safety and effectiveness of primary stenting in this patient group.

Main Methods:

• Prospective, non-randomized, multicenter trial (BRAVISSIMO study).
• Inclusion of 190 patients with TASC A or B aortoiliac lesions across Belgium and Italy.
• Primary endpoint: 12-month primary patency defined by duplex ultrasound and absence of Target Lesion Revascularization (TLR).

Main Results:

• High 12-month primary patency rates: 94.0% for TASC A and 96.5% for TASC B lesions.
• Comparable patency rates between TASC A and B groups, with no statistical significance.
• Specific stent types (Omnilink Elite, Absolute Pro) demonstrated high patency rates.

Conclusions:

• Primary stenting is a preferred endovascular treatment for TASC A/B aortoiliac lesions.
• The BRAVISSIMO study provides robust data supporting endovascular therapy efficacy.
• Further analysis of TASC C/D lesions will offer comprehensive insights into the study's findings.